These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28379102)

  • 21. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries.
    Ghatnekar O; Willis M; Persson U
    J Wound Care; 2002 Feb; 11(2):70-4. PubMed ID: 11901743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The resource impact of wounds on health-care providers in Europe.
    Posnett J; Gottrup F; Lundgren H; Saal G
    J Wound Care; 2009 Apr; 18(4):154-161. PubMed ID: 19349935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost of healing pressure ulcers across multiple health care settings.
    Xakellis GC; Frantz R
    Adv Wound Care; 1996; 9(6):18-22. PubMed ID: 9069752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dressings and topical agents for preventing pressure ulcers.
    Moore ZE; Webster J
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009362. PubMed ID: 23955535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(5):1-142. PubMed ID: 28572866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pressure ulcers, hospital complications, and disease severity: impact on hospital costs and length of stay.
    Allman RM; Goode PS; Burst N; Bartolucci AA; Thomas DR
    Adv Wound Care; 1999; 12(1):22-30. PubMed ID: 10326353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The economic situation of chronic wounds].
    Pelka R
    Krankenpfl J; 1997 Sep; 35(9):338. PubMed ID: 9400147
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of three adjunct cellular/tissue-derived products used in the management of chronic venous leg ulcers.
    Carter MJ; Waycaster C; Schaum K; Gilligan AM
    Value Health; 2014 Dec; 17(8):801-13. PubMed ID: 25498775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The average cost of pressure ulcer management in a community dwelling spinal cord injury population.
    Chan BC; Nanwa N; Mittmann N; Bryant D; Coyte PC; Houghton PE
    Int Wound J; 2013 Aug; 10(4):431-40. PubMed ID: 22715990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic analysis of VenUS I, a randomized trial of two bandages for treating venous leg ulcers.
    Iglesias CP; Nelson EA; Cullum N; Torgerson DJ;
    Br J Surg; 2004 Oct; 91(10):1300-6. PubMed ID: 15382101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economic impact of pressure ulcers among patients in intensive care units. A systematic review.
    McEvoy N; Avsar P; Patton D; Curley G; Kearney CJ; Moore Z
    J Tissue Viability; 2021 May; 30(2):168-177. PubMed ID: 33402275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products.
    Gilligan AM; Waycaster CR; Landsman AL
    J Wound Care; 2015 Mar; 24(3):149-56. PubMed ID: 25764960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are labour-intensive efforts to prevent pressure ulcers cost-effective?
    Mathiesen AS; Nørgaard K; Andersen MF; Møller KM; Ehlers LH
    J Med Econ; 2013 Oct; 16(10):1238-45. PubMed ID: 23926909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economics of pressure-ulcer care: review of the literature on modern versus traditional dressings.
    San Miguel L; Torra i Bou JE; Verdú Soriano J
    J Wound Care; 2007 Jan; 16(1):5-9. PubMed ID: 17334139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the cost and efficacy of leg ulcer care provided in two large UK health authorities.
    Ellison DA; Hayes L; Lane C; Tracey A; McCollum CN
    J Wound Care; 2002 Feb; 11(2):47-51. PubMed ID: 11901738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct cost of dressings for pressure ulcers in hospitalized patients.
    Lima AF; Castilho V; Baptista CM; Rogenski NM; Rogenski KE
    Rev Bras Enferm; 2016; 69(2):290-7. PubMed ID: 27280565
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of venous leg ulcers is costly for the health care and the society. The value of preventive measures should be further investigated according to a study].
    Ragnarson Tennvall G; Hjelmgren J
    Lakartidningen; 2005 Oct 17-23; 102(42):3027-9. PubMed ID: 16294525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pressure-relieving interventions for treating diabetic foot ulcers.
    Lewis J; Lipp A
    Cochrane Database Syst Rev; 2013 Jan; (1):CD002302. PubMed ID: 23440787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.